Do analysts prefer ADXS or BGM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ayala Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 BGM Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, ADXS or BGM?

BGM Group has higher revenue and earnings than Ayala Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ayala Pharmaceuticals $3.24M 11.05 -$48.07M -$5.02 N/A BGM Group $37.92M 3.37 -$19.94M N/A N/A

Is ADXS or BGM more profitable?

Company Net Margins Return on Equity Return on Assets Ayala Pharmaceuticals N/A N/A N/A BGM Group N/A N/A N/A

Do analysts recommend ADXS or RFAI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ayala Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 RF Acquisition Corp II 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher valuation and earnings, ADXS or RFAI?

RF Acquisition Corp II has lower revenue, but higher earnings than Ayala Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ayala Pharmaceuticals $3.24M 11.05 -$48.07M -$5.02 N/A RF Acquisition Corp II N/A N/A N/A N/A N/A

Is ADXS or RFAI more profitable?

Company Net Margins Return on Equity Return on Assets Ayala Pharmaceuticals N/A N/A N/A RF Acquisition Corp II N/A N/A N/A

Do analysts prefer NRXP or ADXS?

NRx Pharmaceuticals currently has a consensus price target of $34.50, indicating a potential upside of 1,177.78%. Given NRx Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe NRx Pharmaceuticals is more favorable than Ayala Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NRx Pharmaceuticals 2 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.43 Ayala Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is NRXP or ADXS more profitable?

Ayala Pharmaceuticals has a net margin of 0.00% compared to NRx Pharmaceuticals' net margin of -691.81%. Company Net Margins Return on Equity Return on Assets NRx Pharmaceuticals -691.81% N/A -63.92% Ayala Pharmaceuticals N/A N/A N/A

Do analysts recommend VTVT or ADXS?

vTv Therapeutics currently has a consensus target price of $55.83, indicating a potential upside of 97.78%. Given vTv Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe vTv Therapeutics is more favorable than Ayala Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score vTv Therapeutics 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.78 Ayala Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is VTVT or ADXS more profitable?

Ayala Pharmaceuticals' return on equity of 0.00% beat vTv Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets vTv Therapeutics N/A -6.27% -5.06% Ayala Pharmaceuticals N/A N/A N/A

Do analysts prefer ADXS or UNCY?

Unicycive Therapeutics has a consensus price target of $18.25, suggesting a potential upside of 389.28%. Given Unicycive Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Unicycive Therapeutics is more favorable than Ayala Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ayala Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Unicycive Therapeutics 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57

Is ADXS or UNCY more profitable?

Ayala Pharmaceuticals' return on equity of 0.00% beat Unicycive Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Ayala Pharmaceuticals N/A N/A N/A Unicycive Therapeutics N/A -91.50% -61.47%

Ayala Pharmaceuticals (ADXS) Competitors

$0.60 0.00 (0.00%)

As of 10/13/2026

Compare

ADXS vs. BGM, RFAI, NRXP, VTVT, and UNCY

Should you buy Ayala Pharmaceuticals stock or one of its competitors? Ayala Pharmaceuticals's main competitors and comparable companies include BGM Group (BGM), RF Acquisition Corp II (RFAI), NRx Pharmaceuticals (NRXP), vTv Therapeutics (VTVT), and Unicycive Therapeutics (UNCY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Ayala Pharmaceuticals compare to BGM Group?

Ayala Pharmaceuticals (NASDAQ:ADXS) and BGM Group (NASDAQ:BGM) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation.

Company	Net Margins	Return on Equity	Return on Assets
Ayala Pharmaceuticals	N/A	N/A	N/A
BGM Group	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ayala Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
BGM Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

7.2% of Ayala Pharmaceuticals shares are owned by institutional investors. 0.6% of Ayala Pharmaceuticals shares are owned by insiders. Comparatively, 58.7% of BGM Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

BGM Group has higher revenue and earnings than Ayala Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ayala Pharmaceuticals	$3.24M	11.05	-$48.07M	-$5.02	N/A
BGM Group	$37.92M	3.37	-$19.94M	N/A	N/A

In the previous week, BGM Group had 2 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 2 mentions for BGM Group and 0 mentions for Ayala Pharmaceuticals. BGM Group's average media sentiment score of 0.39 beat Ayala Pharmaceuticals' score of 0.00 indicating that BGM Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Ayala Pharmaceuticals	Neutral
BGM Group	Neutral

Ayala Pharmaceuticals has a beta of 1.75, indicating that its share price is 75% more volatile than the broader market. Comparatively, BGM Group has a beta of 1.85, indicating that its share price is 85% more volatile than the broader market.

Summary

BGM Group beats Ayala Pharmaceuticals on 7 of the 9 factors compared between the two stocks.

How does Ayala Pharmaceuticals compare to RF Acquisition Corp II?

Ayala Pharmaceuticals (NASDAQ:ADXS) and RF Acquisition Corp II (NASDAQ:RFAI) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, media sentiment, risk, institutional ownership and dividends.

RF Acquisition Corp II has lower revenue, but higher earnings than Ayala Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ayala Pharmaceuticals	$3.24M	11.05	-$48.07M	-$5.02	N/A
RF Acquisition Corp II	N/A	N/A	N/A	N/A	N/A

Ayala Pharmaceuticals has a beta of 1.75, indicating that its share price is 75% more volatile than the broader market. Comparatively, RF Acquisition Corp II has a beta of 1.29, indicating that its share price is 29% more volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
Ayala Pharmaceuticals	N/A	N/A	N/A
RF Acquisition Corp II	N/A	N/A	N/A

7.2% of Ayala Pharmaceuticals shares are held by institutional investors. 0.6% of Ayala Pharmaceuticals shares are held by company insiders. Comparatively, 39.1% of RF Acquisition Corp II shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, RF Acquisition Corp II had 5 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 5 mentions for RF Acquisition Corp II and 0 mentions for Ayala Pharmaceuticals. RF Acquisition Corp II's average media sentiment score of 0.51 beat Ayala Pharmaceuticals' score of 0.00 indicating that RF Acquisition Corp II is being referred to more favorably in the news media.

Company	Overall Sentiment
Ayala Pharmaceuticals	Neutral
RF Acquisition Corp II	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ayala Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
RF Acquisition Corp II	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

RF Acquisition Corp II beats Ayala Pharmaceuticals on 4 of the 7 factors compared between the two stocks.

How does Ayala Pharmaceuticals compare to NRx Pharmaceuticals?

NRx Pharmaceuticals (NASDAQ:NRXP) and Ayala Pharmaceuticals (NASDAQ:ADXS) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, profitability, risk, analyst recommendations, dividends and institutional ownership.

4.3% of NRx Pharmaceuticals shares are held by institutional investors. Comparatively, 7.2% of Ayala Pharmaceuticals shares are held by institutional investors. 6.4% of NRx Pharmaceuticals shares are held by company insiders. Comparatively, 0.6% of Ayala Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

NRx Pharmaceuticals currently has a consensus price target of $34.50, indicating a potential upside of 1,177.78%. Given NRx Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe NRx Pharmaceuticals is more favorable than Ayala Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NRx Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43
Ayala Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Ayala Pharmaceuticals has a net margin of 0.00% compared to NRx Pharmaceuticals' net margin of -691.81%.

Company	Net Margins	Return on Equity	Return on Assets
NRx Pharmaceuticals	-691.81%	N/A	-63.92%
Ayala Pharmaceuticals	N/A	N/A	N/A

NRx Pharmaceuticals has a beta of 2.07, indicating that its share price is 107% more volatile than the broader market. Comparatively, Ayala Pharmaceuticals has a beta of 1.75, indicating that its share price is 75% more volatile than the broader market.

In the previous week, NRx Pharmaceuticals had 1 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 1 mentions for NRx Pharmaceuticals and 0 mentions for Ayala Pharmaceuticals. Ayala Pharmaceuticals' average media sentiment score of 0.00 beat NRx Pharmaceuticals' score of -0.26 indicating that Ayala Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
NRx Pharmaceuticals	Neutral
Ayala Pharmaceuticals	Neutral

NRx Pharmaceuticals has higher earnings, but lower revenue than Ayala Pharmaceuticals. NRx Pharmaceuticals is trading at a lower price-to-earnings ratio than Ayala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NRx Pharmaceuticals	$1.23M	95.05	-$28.62M	-$0.55	N/A
Ayala Pharmaceuticals	$3.24M	11.05	-$48.07M	-$5.02	N/A

Summary

NRx Pharmaceuticals beats Ayala Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Ayala Pharmaceuticals compare to vTv Therapeutics?

vTv Therapeutics (NASDAQ:VTVT) and Ayala Pharmaceuticals (NASDAQ:ADXS) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk.

vTv Therapeutics has a beta of 0.21, suggesting that its share price is 79% less volatile than the broader market. Comparatively, Ayala Pharmaceuticals has a beta of 1.75, suggesting that its share price is 75% more volatile than the broader market.

17.5% of vTv Therapeutics shares are held by institutional investors. Comparatively, 7.2% of Ayala Pharmaceuticals shares are held by institutional investors. 6.0% of vTv Therapeutics shares are held by insiders. Comparatively, 0.6% of Ayala Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, vTv Therapeutics had 9 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 9 mentions for vTv Therapeutics and 0 mentions for Ayala Pharmaceuticals. vTv Therapeutics' average media sentiment score of 0.27 beat Ayala Pharmaceuticals' score of 0.00 indicating that vTv Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
vTv Therapeutics	Neutral
Ayala Pharmaceuticals	Neutral

vTv Therapeutics currently has a consensus target price of $55.83, indicating a potential upside of 97.78%. Given vTv Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe vTv Therapeutics is more favorable than Ayala Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
vTv Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Ayala Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Ayala Pharmaceuticals' return on equity of 0.00% beat vTv Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
vTv Therapeutics	N/A	-6.27%	-5.06%
Ayala Pharmaceuticals	N/A	N/A	N/A

vTv Therapeutics has higher earnings, but lower revenue than Ayala Pharmaceuticals. vTv Therapeutics is trading at a lower price-to-earnings ratio than Ayala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
vTv Therapeutics	$1.02M	109.05	-$26.97M	-$1.06	N/A
Ayala Pharmaceuticals	$3.24M	11.05	-$48.07M	-$5.02	N/A

Summary

vTv Therapeutics beats Ayala Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Ayala Pharmaceuticals compare to Unicycive Therapeutics?

Ayala Pharmaceuticals (NASDAQ:ADXS) and Unicycive Therapeutics (NASDAQ:UNCY) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends, media sentiment and earnings.

Unicycive Therapeutics has lower revenue, but higher earnings than Ayala Pharmaceuticals. Unicycive Therapeutics is trading at a lower price-to-earnings ratio than Ayala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ayala Pharmaceuticals	$3.24M	11.05	-$48.07M	-$5.02	N/A
Unicycive Therapeutics	$680K	152.77	-$26.56M	-$1.75	N/A

Ayala Pharmaceuticals' return on equity of 0.00% beat Unicycive Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ayala Pharmaceuticals	N/A	N/A	N/A
Unicycive Therapeutics	N/A	-91.50%	-61.47%

7.2% of Ayala Pharmaceuticals shares are owned by institutional investors. Comparatively, 40.4% of Unicycive Therapeutics shares are owned by institutional investors. 0.6% of Ayala Pharmaceuticals shares are owned by insiders. Comparatively, 6.0% of Unicycive Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Unicycive Therapeutics has a consensus price target of $18.25, suggesting a potential upside of 389.28%. Given Unicycive Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Unicycive Therapeutics is more favorable than Ayala Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ayala Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Unicycive Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

In the previous week, Unicycive Therapeutics had 11 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 11 mentions for Unicycive Therapeutics and 0 mentions for Ayala Pharmaceuticals. Unicycive Therapeutics' average media sentiment score of 0.06 beat Ayala Pharmaceuticals' score of 0.00 indicating that Unicycive Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Ayala Pharmaceuticals	Neutral
Unicycive Therapeutics	Neutral

Ayala Pharmaceuticals has a beta of 1.75, suggesting that its stock price is 75% more volatile than the broader market. Comparatively, Unicycive Therapeutics has a beta of 1.83, suggesting that its stock price is 83% more volatile than the broader market.

Summary

Unicycive Therapeutics beats Ayala Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

Get Ayala Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ADXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ADXS vs. The Competition

Export

Metric	Ayala Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$35.79M	$12.41B	$7.28B	$12.93B
Dividend Yield	N/A	2.63%	2.51%	22.89%
P/E Ratio	-0.08	807.82	275.40	25.27
Price / Sales	11.05	748.52	562.90	78.90
Price / Cash	N/A	86.65	77.16	53.04
Price / Book	-0.29	9.20	10.55	5.93
Net Income	-$48.07M	$2.84B	$3.50B	$380.91M
7 Day Performance	N/A	-4.07%	-3.94%	-4.21%
1 Month Performance	N/A	-8.13%	-8.33%	-7.05%
1 Year Performance	N/A	-5.87%	2.44%	-4.87%

Ayala Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ADXS Ayala Pharmaceuticals	N/A	$0.60 flat	N/A	N/A	$35.79M	$3.24M	N/A	20
BGM BGM Group	0.5901 of 5 stars	$10.75 +7.9%	N/A	-96.5%	$136.39M	$47.90M	N/A	471	Short Interest Increase Gap Down
RFAI RF Acquisition Corp II	1.7506 of 5 stars	$38.82 +2.8%	N/A	+264.3%	$136.36M	N/A	N/A	2	Short Interest Decrease Gap Down
NRXP NRx Pharmaceuticals	1.9027 of 5 stars	$2.85 -1.4%	$34.50 +1,110.5%	-13.5%	$123.39M	$3.39M	N/A	29
VTVT vTv Therapeutics	3.1466 of 5 stars	$31.18 +3.7%	$55.83 +79.1%	+29.4%	$122.82M	$36.84M	N/A	26	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ADXS) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ayala Pharmaceuticals (ADXS) Competitors

ADXS vs. BGM, RFAI, NRXP, VTVT, and UNCY

How does Ayala Pharmaceuticals compare to BGM Group?

Summary

How does Ayala Pharmaceuticals compare to RF Acquisition Corp II?

Summary

How does Ayala Pharmaceuticals compare to NRx Pharmaceuticals?

Summary

How does Ayala Pharmaceuticals compare to vTv Therapeutics?

Summary

How does Ayala Pharmaceuticals compare to Unicycive Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADXS vs. The Competition

Ayala Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ayala Pharmaceuticals (ADXS) Competitors

ADXS vs. BGM, RFAI, NRXP, VTVT, and UNCY

How does Ayala Pharmaceuticals compare to BGM Group?

Is ADXS or BGM more profitable?

Do analysts prefer ADXS or BGM?

Do insiders and institutionals hold more shares of ADXS or BGM?

Which has stronger earnings & valuation, ADXS or BGM?

Does the media favor ADXS or BGM?

Which has more risk & volatility, ADXS or BGM?

Summary

How does Ayala Pharmaceuticals compare to RF Acquisition Corp II?

Which has higher valuation and earnings, ADXS or RFAI?

Which has more risk & volatility, ADXS or RFAI?

Is ADXS or RFAI more profitable?

Do institutionals & insiders believe in ADXS or RFAI?

Does the media favor ADXS or RFAI?

Do analysts recommend ADXS or RFAI?

Summary

How does Ayala Pharmaceuticals compare to NRx Pharmaceuticals?

Do insiders & institutionals believe in NRXP or ADXS?

Do analysts prefer NRXP or ADXS?

Is NRXP or ADXS more profitable?

Which has more risk & volatility, NRXP or ADXS?

Does the media refer more to NRXP or ADXS?

Which has better valuation and earnings, NRXP or ADXS?

Summary

How does Ayala Pharmaceuticals compare to vTv Therapeutics?

Which has more risk and volatility, VTVT or ADXS?

Do institutionals and insiders believe in VTVT or ADXS?

Does the media refer more to VTVT or ADXS?

Do analysts recommend VTVT or ADXS?

Is VTVT or ADXS more profitable?

Which has stronger earnings & valuation, VTVT or ADXS?

Summary

How does Ayala Pharmaceuticals compare to Unicycive Therapeutics?

Which has better valuation and earnings, ADXS or UNCY?

Is ADXS or UNCY more profitable?

Do institutionals & insiders hold more shares of ADXS or UNCY?

Do analysts prefer ADXS or UNCY?

Does the media prefer ADXS or UNCY?

Which has more volatility and risk, ADXS or UNCY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADXS vs. The Competition

Ayala Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools